PO86 | Emicizumab in patients with moderate hemophilia A and severe bleeding phenotype: single-center real-world experience
Background and Aims: The role of prophylaxis in moderate hemophilia A (HA) patients is less clear than in severe HA, given their variable bleeding phenotype. A relevant portion of moderate HA patients may have a severe bleeding phenotype, characterized by frequent hemarthrosis, with a consequent hi...
Saved in:
| Format: | Article |
|---|---|
| Language: | English |
| Published: |
PAGEPress Publications
2025-08-01
|
| Series: | Bleeding, Thrombosis and Vascular Biology |
| Subjects: | |
| Online Access: | https://www.btvb.org/btvb/article/view/355 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|